Revenue grew 9.9% to SEK 1.826 billion, driven by strong RX demand and stable gross margins. Profitability improved, with an adjusted EBIT margin of 5.4%, and the Varberg facility is set to boost future efficiency. Net cash position remains strong.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.